Stockscreener 앱 받기
89.70
0.38%
0.34
시간 외 거래:
91.30
1.60
+1.78%
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Mirum Pharma wins FDA nod for Atebrioz - The Pharma Letter
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder - Seeking Alpha
MIRM5806400 Bond Profile: Coupon and Redemption - TradingView
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older - Mugglehead Investment Magazine
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva - Business Wire
Mirum Pharmaceuticals wins Bay Area's 14th drug approval this year - The Business Journals
Why is Mirum Pharmaceuticals stock gaining today? By Investing.com - Investing.com Canada
US FDA approves Mirum's drug for rare bone disorder - Reuters
Bay Area company readies for decision on drug to treat alarming 'stone man' syndrome - The Business Journals
Mirum Pharmaceuticals stock trades at USD 98.22 as targets reach USD 137.31 - AD HOC NEWS
(MIRM) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer - Contract Pharma
Mirum Pharmaceuticals stock pulls back as Bank of America reveals new stake and valuation stays belo - AD HOC NEWS
Mirum Pharmaceuticals Falls 7.1% as Investors Appear to Reassess Near-Term Biotech Catalysts - Moomoo
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events - Seeking Alpha
Mirum Pharmaceuticals at Morgan Stanley conference: growth meets key catalysts - Investing.com Canada
Mirum Pharmaceuticals Chief Financial Officer Sold Shares Worth Over $978K - TradingView
Mirum Pharma (MIRM) officer to sell shares to cover equity taxes - Stock Titan
Mirum Pharmaceuticals (MIRM) CFO offloads shares after RSUs vest - Stock Titan
Mirum Pharmaceuticals at H.C. Wainwright conference: growth, catalysts By Investing.com - Investing.com UK
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst - Seeking Alpha
MIRM: Commercial growth, pipeline catalysts, and global expansion position the business for continued momentum - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Citizens reiterates Mirum Pharmaceuticals stock rating at outperform By Investing.com - Investing.com Canada
Precision Trading with Mirum Pharmaceuticals Inc. (MIRM) Risk Zones - Stock Traders Daily
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com India
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push - Investing.com India
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Hires LMH Strategic Solutions - Legis1
Mirum Pharmaceuticals, Inc. Announces Management Changes - marketscreener.com
Chief medical shake-up at Mirum Pharmaceuticals (NASDAQ: MIRM) includes new leader and exit deal - Stock Titan
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer - Yahoo Finance
MIRM stock gains on strong Q2 2026 revenue growth - ad-hoc-news.de
Mirum Pharmaceuticals SVP Howe Jolanda Disposes of 658 Shares at $100 Each (NASDAQ: MIRM) - Kalkine Media
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? - Yahoo Finance
Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals global controller sells $65,800 in stock - investing.com
Mirum Pharmaceuticals SVP Jolanda Howe Sells 658 Shares via 10b5-1 Trading Plan - Kalkine Media
Mirum Pharmaceuticals CEO Christopher Peetz Executes Stock Option and Sells Shares Under 10b5-1 Plan - Kalkine Media
Mirum Pharma (NASDAQ: MIRM) exec sells 658 shares under preset plan - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO trades 30,000 shares under preset plan - Stock Titan
Officer who sold $4M of Mirum (NASDAQ: MIRM) stock plans another sale - Stock Titan
Five investor conferences are on Mirum’s September schedule - Stock Titan
Mirum (NASDAQ: MIRM) investor plans Sept. stock sale after 40,000 shares sold - Stock Titan
Trading Systems Reacting to (MIRM) Volatility - Stock Traders Daily
Mirum Pharmaceuticals Inc (08D) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc (08D) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Mirum Pharmaceuticals Inc. (MIRM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Citizens reiterates Mirum Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
MIRM5806400 Bond Profile — Key Metrics - TradingView
Citizens raises Mirum Pharmaceuticals price target to $146 - scanx.trade
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
US FDA approves Regeneron's rare bone disorder drug - Reuters
Mirum Pharmaceuticals Insider Sold Shares Worth $4,000,000, According to a Recent SEC Filing - finance.yahoo.com
3.06%
2.55%
자본화:
|
볼륨(24시간):